WO2018170005A1 - Personalized contraceptive formulations - Google Patents

Personalized contraceptive formulations Download PDF

Info

Publication number
WO2018170005A1
WO2018170005A1 PCT/US2018/022247 US2018022247W WO2018170005A1 WO 2018170005 A1 WO2018170005 A1 WO 2018170005A1 US 2018022247 W US2018022247 W US 2018022247W WO 2018170005 A1 WO2018170005 A1 WO 2018170005A1
Authority
WO
WIPO (PCT)
Prior art keywords
amount
lng
ethinyl estradiol
pounds
equivalent
Prior art date
Application number
PCT/US2018/022247
Other languages
English (en)
French (fr)
Inventor
Agis Kydonieus
Elizabeth I.O. GARNER
III Joseph A. CHIODO
Joseph A. D'URSO
Original Assignee
Agile Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020197029740A priority Critical patent/KR20190124296A/ko
Application filed by Agile Therapeutics, Inc. filed Critical Agile Therapeutics, Inc.
Priority to AU2018235778A priority patent/AU2018235778B2/en
Priority to CA3056210A priority patent/CA3056210A1/en
Priority to MX2019010794A priority patent/MX2019010794A/es
Priority to US16/494,123 priority patent/US20200129524A1/en
Priority to BR112019019057A priority patent/BR112019019057A2/pt
Priority to RU2019132428A priority patent/RU2796919C2/ru
Priority to CN201880018378.0A priority patent/CN110740713A/zh
Priority to JP2019550577A priority patent/JP2020511463A/ja
Priority to EP18766673.0A priority patent/EP3595597A4/en
Publication of WO2018170005A1 publication Critical patent/WO2018170005A1/en
Priority to IL26907119A priority patent/IL269071A/en
Priority to JP2023132791A priority patent/JP2023156451A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PCT/US2018/022247 2017-03-15 2018-03-13 Personalized contraceptive formulations WO2018170005A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BR112019019057A BR112019019057A2 (pt) 2017-03-15 2018-03-13 formulações contraceptivas personalizadas
AU2018235778A AU2018235778B2 (en) 2017-03-15 2018-03-13 Personalized contraceptive formulations
CA3056210A CA3056210A1 (en) 2017-03-15 2018-03-13 Personalized contraceptive formulations
MX2019010794A MX2019010794A (es) 2017-03-15 2018-03-13 Formulaciones de anticonceptivo personalizadas.
US16/494,123 US20200129524A1 (en) 2017-03-15 2018-03-13 Personalized contraceptive formulations
KR1020197029740A KR20190124296A (ko) 2017-03-15 2018-03-13 개인맞춤형 피임용 제제
RU2019132428A RU2796919C2 (ru) 2017-03-15 2018-03-13 Композиции для персонализированной контрацепции
EP18766673.0A EP3595597A4 (en) 2017-03-15 2018-03-13 PERSONALIZED CONTRACEPTIVE FORMULATIONS
JP2019550577A JP2020511463A (ja) 2017-03-15 2018-03-13 個別化避妊製剤
CN201880018378.0A CN110740713A (zh) 2017-03-15 2018-03-13 个性化避孕制剂
IL26907119A IL269071A (en) 2017-03-15 2019-09-02 Personal contraceptive formulations
JP2023132791A JP2023156451A (ja) 2017-03-15 2023-08-17 個別化避妊製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471640P 2017-03-15 2017-03-15
US62/471,640 2017-03-15

Publications (1)

Publication Number Publication Date
WO2018170005A1 true WO2018170005A1 (en) 2018-09-20

Family

ID=63522527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/022247 WO2018170005A1 (en) 2017-03-15 2018-03-13 Personalized contraceptive formulations

Country Status (11)

Country Link
US (1) US20200129524A1 (ko)
EP (1) EP3595597A4 (ko)
JP (2) JP2020511463A (ko)
KR (1) KR20190124296A (ko)
CN (1) CN110740713A (ko)
AU (1) AU2018235778B2 (ko)
BR (1) BR112019019057A2 (ko)
CA (1) CA3056210A1 (ko)
IL (1) IL269071A (ko)
MX (1) MX2019010794A (ko)
WO (1) WO2018170005A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679114B2 (en) * 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100178323A1 (en) * 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
US20120263784A1 (en) * 2009-10-12 2012-10-18 Lyka Labs Limited Emergency contraceptive
US20140256690A1 (en) * 2013-03-08 2014-09-11 Agile Therapeutics, Inc. Contraceptive method
US20150283152A1 (en) * 2012-11-12 2015-10-08 Naari Ag Levonorgestrel-Only-Composition For Optimized Oral Contraception With Defined Levonorgestrel Content, Dosage Regimen And Pharmaceutical Preparation
WO2016187269A1 (en) * 2015-05-18 2016-11-24 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241092A1 (en) * 2005-04-15 2006-10-26 Anderson Freedolph D Contraceptive regimens for lower-weight women
EP3108889A1 (en) * 2015-06-23 2016-12-28 Philippe Perrin Drospirenone-based contraceptive for a female patient affected with excess weight

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100178323A1 (en) * 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
US20120263784A1 (en) * 2009-10-12 2012-10-18 Lyka Labs Limited Emergency contraceptive
US20150283152A1 (en) * 2012-11-12 2015-10-08 Naari Ag Levonorgestrel-Only-Composition For Optimized Oral Contraception With Defined Levonorgestrel Content, Dosage Regimen And Pharmaceutical Preparation
US20140256690A1 (en) * 2013-03-08 2014-09-11 Agile Therapeutics, Inc. Contraceptive method
WO2016187269A1 (en) * 2015-05-18 2016-11-24 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects

Also Published As

Publication number Publication date
BR112019019057A2 (pt) 2020-04-22
IL269071A (en) 2019-11-28
CN110740713A (zh) 2020-01-31
RU2019132428A3 (ko) 2021-10-29
EP3595597A4 (en) 2020-11-18
AU2018235778B2 (en) 2024-04-18
MX2019010794A (es) 2020-01-27
KR20190124296A (ko) 2019-11-04
EP3595597A1 (en) 2020-01-22
RU2019132428A (ru) 2021-04-15
CA3056210A1 (en) 2018-09-20
JP2020511463A (ja) 2020-04-16
AU2018235778A1 (en) 2019-10-31
US20200129524A1 (en) 2020-04-30
JP2023156451A (ja) 2023-10-24

Similar Documents

Publication Publication Date Title
Gemzell-Danielsson et al. Emergency contraception: potential role of ulipristal acetate
AU2016264137B2 (en) Contraceptive compositions and methods for improved efficacy and modulation of side effects
US11103515B2 (en) Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
JPH11508538A (ja) ホルモン避妊用薬剤の複合調剤、キット及び避妊方法
JPH04290830A (ja) 避妊薬処方物
WO2008150547A1 (en) Pregnancy hormone combination for treatment of autoimmune diseases
Borgelt-Hansen Oral contraceptives: an update on health benefits and risks
Gerrits et al. Pharmacokinetic profile of nomegestrol acetate and 17β-estradiol after multiple and single dosing in healthy women
PL213122B1 (pl) Zestaw i preparat zawierajacy estrogen i progestagen
JP2023156451A (ja) 個別化避妊製剤
Ornstein et al. Hormonal contraception in adolescents: special considerations
JP2009539759A (ja) 経口１相性低用量避妊薬に対する新しい投与計画
RU2796919C2 (ru) Композиции для персонализированной контрацепции
JP2003511399A (ja) 女性避妊薬の成分としてのメソプロゲスチン（プロゲステロン受容体モジュレーター）
US20240156838A1 (en) Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects
US11376263B2 (en) Cyproterone acetate compositions and uses thereof
Tri-Cira Pr Tri-Cira 21
Kaunitz et al. Existing and Emerging Shorter-Acting Nondaily Hormonal Contraceptives
Palshetkar et al. Tackling PCOS with Hormonal Contraceptives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18766673

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3056210

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019550577

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019019057

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197029740

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018766673

Country of ref document: EP

Effective date: 20191015

ENP Entry into the national phase

Ref document number: 2018235778

Country of ref document: AU

Date of ref document: 20180313

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112019019057

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190913